Cancer is one of the leading causes of death in the United States along with heart disease.
The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic …

The goal of this review is to highlight the wide range of biological activities displayed by
purines, with particular emphasis on new purine-based agents which find potential …

Hairy cell leukemia (HCL) is a chronic B cell malignancy characterized by the diffuse
infiltration of bone marrow and spleen by cells displaying a typical “hairy” morphology …

Much progress has been made in our understanding of Interferon biology since its initial
description by Isaacs and Lindenmann in 1957.[1] Type I Interferons have well established …

2-chlorodeoxyadenosine (2-CdA), a purine analog, has become universally accepted as the
agent of choice in treating hairy cell leukemia (HCL). However, few studies have reported …

Interferons, a group of cytokines with antiangiogenic, direct antitumour and
immunostimulating properties, have shown significant activity against osteosarcoma in vitro …

Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by
splenomegaly, pancytopenia and circulating lymphocytes displaying prominent cytoplasmic …

The purine nucleoside analogues (PNAs), fludarabine (FA), 2-CdA (2-
chlorodeoxyadenosine, 2-CdA) and pentostatin (2'-deoxycoformycin, DCF) represent a …

Hairy cell leukemia (HCL) is part of the low-grade non-Hodgkin lymphoma family and
represents approximately 2% of all leukemias. Treatment with splenectomy and interferon-α …

Background: Elective laparoscopic splenectomy (LS) achieves excellent results for benign
hematologic diseases. The role of LS for hematologic malignancies is harder to define …